Associations between TLR9 polymorphisms and cancer risk: Evidence from an updated meta-analysis of 25,685 subjects

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 19, 2014, Pages 8279-8285

  Wan, Guo Xing ^a   Cao, Yu Wen ^a   Li, Wen Qin ^a   Li, Yu Cong ^a   Zhang, Wen Jie ^a   Li, Feng ^a  

^a SHIHEZI UNIVERSITY   (China)

Author keywords

Cancer risk; Meta analysis; Polymorphisms; Toll like receptor 9

Indexed keywords

TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; NEOPLASM; PROGNOSIS; RISK FACTOR;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TOLL-LIKE RECEPTOR 9;

EID: 84908375489     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.19.8279     Document Type: Article

References (41)

1. Aderem A, Ulevitch RJ (2000). Toll-like receptors in the induction of the innate immune response. Nature, 406, 782-7.
2. Ashton KA, Proietto A, Otton G, et al (2010). Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer, 10, 382.
3. Bondar T, Medzhitov R (2013). The origins of tumor-promoting inflammation. Cancer Cell, 24, 143-4.
4. Carvalho A, Cunha C, Almeida AJ, et al (2012). The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma.Genes Immun, 13, 197-201.
5. Castro FA, Forsti A, Buch S, et al (2011). TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer, 47, 1203-10.
6. Chen X, Wang S, Liu L, et al (2012). A genetic variant in the promoter region of Toll-like receptor 9 and cervical cancer susceptibility. DNA Cell Biol, 31, 766-71.
7. Chuang TH, Ulevitch RJ (2000). Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw, 11, 372-784.
8. Cochran WG (1950). The comparison of percentages in matched samples. Biometrika, 37, 256-66.
9. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
10. Etokebe GE, Knezevic J, Petricevic B, et al (2009). Singlenucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol Biomarkers, 13, 729-34.
11. Fehri E, Ennaifer E, Ardhaoui M, et al (2014). Expression of Toll-like receptor 9 increases with progression of cervical neoplasia in Tunisian women-a comparative analysis of condyloma, cervical intraepithelial neoplasia and invasive carcinoma. Asian Pac J Cancer Prev, 15, 6145-50.
12. Grimm M, Kim M, Rosenwald A, et al (2010). Toll-like receptor (TLR) 7 and TLR8 expression on CD133+cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer, 46, 2849-57.
13. Hao Y, Yuan JL, Abudula A, et al (2014). TLR9 expression in uterine cervical lesions of Uyghur women correlate with cervical cancer progression and selective silencing of human papillomavirus 16 E6 and E7 oncoproteins in vitro. Asian Pac J Cancer Prev, 15, 5867-72.
14. Hemmi H, Takeuchi O, Kawai T, et al (2000). A Toll-like receptor recognizes bacterial DNA. Nature, 408, 740-5.
15. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
16. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
17. Hold GL, Rabkin CS, Gammon MD, et al (2009). CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev, 18, 117-9.
18. Huang B, Zhao J, Li H, et al (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res, 65, 5009-14.
19. Kutikhin AG (2011). Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol, 72, 1095-116.
20. Lai ZZ, Ni Zhang, Pan XL, et al (2013). Toll-like receptor 9 (TLR9) gene polymorphisms associated with increased susceptibility of human papillomavirus-16 infection in patients with cervical cancer. J Int Med Res, 41, 1027-36.
21. Latz E, Schoenemeyer A, Visintin A, et al (2004). TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol, 5, 190-8.
22. Li S, Dai Q, Yang Z (2012). Association between Toll-like receptor 9 polymorphisms and INF-γ expression with colorectal carcinoma. Sichuan J Anatomy, 20, 12-5.
23. Mandal RK, George GP, Mittal RD (2012). Association of Tolllike receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population. Mol Biol Rep, 39, 7263-9.
24. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
25. Mantovani A, Allavena P, Sica A, et al (2008). Cancer-related inflammation. Nature, 454, 436-44.
26. Miedema KG, Tissing WJ, Te PE, et al (2012). Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease. Leukemia, 26, 1203-10.
27. Mollaki V, Georgiadis T, Tassidou A, et al (2009). Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. J Hum Genet, 54, 655-9.
28. Murad YM, Clay TM, Lyerly HK, et al (2007). CPG-7909 (PF- 3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther, 7, 1257-667.
29. Nieters A, Beckmann L, Deeg E, et al (2006). Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun, 7, 615-24.
30. Noack J, Jordi M, Zauner L, et al (2012). TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism polymorphism. Cell Death Dis, 21, 323.
31. Oldenburg M, Kruger A, Ferstl R, et al (2012). TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistanceforming modification. Science, 337, 1111-5.
32. Pandey S, Mittal B, Srivastava M, et al (2011). Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep, 38, 4715-21.
33. Resler AJ, Malone KE, Johnson LG, et al (2013). Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer, 13, 219.
34. Roszak A, Lianeri M, Sowinska A, et al (2012). Involvement of Toll-like receptor 9 polymorphism in cervical cancer development. Mol Biol Rep, 39, 8425-30.
35. Singh V, Srivastava N, Kapoor R, et al (2013). Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population. Arch Med Res, 44, 54-61.
36. Wang X, Xue L, Yang Y, et al (2013). TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One, 8, 65731.
37. Xie J, Jiang S, Shi M, et al (2012). The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer, 12, 57.
38. Zeng H, Pan K, Zhang Y, et al (2011). The correlation between polymorphisms of Toll-like receptor 2 and Toll-like receptor 9and susceptibility to gastric cancer. Chin J Pre Med, 45, 588-92.
39. Zhang H, Ma H, Li L, et al (2013). Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One, 8, 69366.
40. Zhang K, Zhou B, Wang Y, et al (2013). The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer, 49, 946-54.
41. Zhang L, Qin H, Guan X, et al (2013). The TLR9 gene polymorphisms and the risk of cancer: evidence from a meta-analysis. PLoS One, 8, 71785.